(Q38999130)

8 September 2017

1 reference

title

TP53 Mutations in Breast and Ovarian Cancer (English)

1 reference

8 September 2017

1 reference

Anne-Lise Børresen-Dale

series ordinal

3

object named as

Anne-Lise Børresen-Dale

1 reference

8 September 2017

1

Laxmi Silwal-Pandit

1 reference

8 September 2017

2

Anita Langerød

1 reference

8 September 2017

language of work or name

1 reference

4 November 2016

1 reference

Cold Spring Harbor Perspectives in Medicine

8 September 2017

published in

1 reference

8 September 2017

volume

7

1 reference

8 September 2017

issue

1

1 reference

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Punctuated evolution of prostate cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Estrogen receptor prevents p53-dependent apoptosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

p53 in breast cancer subtypes and new insights into response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Unravelling mechanisms of p53-mediated tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

21 January 2018

TP53 and breast cancer

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The consequence of oncomorphic TP53 mutations in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

When mutants gain new powers: news from the mutant p53 field.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

APOBEC3B is an enzymatic source of mutation in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Emerging landscape of oncogenic signatures across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

BRCAness: a deeper insight into basal-like breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mutant p53: one name, many proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

New concepts in breast cancer genomics and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Links between mutant p53 and genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mutation and cancer: statistical study of retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

21 January 2018

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

p53 Research: the past thirty years and the next thirty years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

21 January 2018

p53-based cancer therapy

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

TP53 mutations in human cancer: database reassessment and prospects for the next decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mutational processes molding the genomes of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The life history of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

TP53 mutations in human cancers: origins, consequences, and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mutant p53 gain-of-function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Whole-genome characterization of chemoresistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

21 January 2018

TP53 and ovarian cancer

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

The landscape of cancer genes and mutational processes in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

Molecular Subtypes of High-Grade Serous Ovarian Cancer: The Holy Grail?

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026252

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

21 January 2018

1 reference

12 December 2020

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer

1 reference

12 December 2020

Mutant p53 gain of function is interwoven into the hallmarks of cancer

1 reference

12 December 2020

The changing view of high-grade serous ovarian cancer

1 reference

12 December 2020

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

1 reference

12 December 2020

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance

1 reference

12 December 2020

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

1 reference

12 December 2020

A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

1 reference

12 December 2020

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis

1 reference

12 December 2020

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome

1 reference

12 December 2020

10.1101/CSHPERSPECT.A026252

Identifiers

DOI

1 reference

8 September 2017

0 references

1 reference